Sen. Cassidy: Biosimilars Uptake Would Increase By Making Patients Pay More For Innovator Products
December 07, 2016
Sen. Bill Cassidy (R-LA) argued Wednesday (Dec. 7) that making patients pay more for innovator biologics would increase uptake in biosimilars, while also maintaining that his office is exploring ways to address drug pricing in the upcoming user fee authorizations. Uptake and availability of biosimilars, which many have seen as a way to address the high-cost of biologic medicines, was a focus of key lawmakers during a Wednesday policy briefing on biosimilars hosted by The Atlantic . Cassidy cited his...
Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting as the Trump administration and congressional Republicans take on the dismantling and replacement of the Affordable Care Act.